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Abstract 
Purpose: To compare fungal strains including Aspergillus flavipes GCBL-72, Aspergillus flavus GCBL-
60, and Aspergillus niger GCBL-45 and determine whether solid- or liquid-state fermentation (SSF or 
LSF) is more appropriate for lovastatin production using various inexpensive raw materials. 
Methods: LSF and SSF techniques were used to produce the drug lovastatin. High-performance liquid 
chromatography was performed out to quantify lovastatin production. A kinetic growth model was 
applied to estimate product formation at the expense of substrate utilization. 
Results: Aspergillus flavus GCBL-60 was a superior lovastatin-producing strain consuming wheat bran 
as the raw material in SSF. The optimum lovastatin production was 28.36 ± 0.76 mg/100mL at 35 °C, 
pH 5.5, inoculum size 2 mL, 96 h incubation time, and 60 % moisture content. Evaluation of the kinetic 
growth parameters for lovastatin production confirmed that product formation was improved after 
fermentation parameter optimization. 
Conclusion: Our results indicate that Aspergillus flavus GCBL-60 was best lovastatin-producing strain 
and that SSF was superior to LSF for maximum production. Careful optimization can enhance product 
formation.  
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Lovastatin has an important role in lowering 
blood cholesterol levels in both human and 
animals, thus diminishing the risk of 
hypercholesterolemia. It works by inhibiting the 
3-hydroxy-3-methylglutaryl coenzyme A (HMG 
CoA) reductase, thereby limiting the rate of 
cholesterol synthesis [1]. This compound is 
produced as a fungal secondary metabolite. 
Simvastatin can be derived from fermented 
lovastatin by enzymatic deacylation of lovastatin. 
Various Aspergillus species such as Aspergillus 
niger, Aspergillus terreus, Aspergillus flavus, 
Aspergillus flavipes, Aspergillus parasiticus and 
some Monascus species including Monascus 
rubber, Monascus paxi, Monascus anka, and 
Monascus purpureus can produce this 
compound [2,3].  
 
Lovastatin was first isolated from Monascus 
rubber for commercial purposes, but Aspergillus 
terreus remains the organism of choice for 
lovastatin biosynthesis. The lovastatin produced 
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in fermentation broth medium is the open 
hydroxy form, which is the biologically active 
form. The synthetic form of lovastatin is always 
the lactone form, which is converted to the open 
hydroxy acid form in vivo (Fig. 1) when 
administered to patients [4]. The solid-state 
fermentation (SSF) technique is considered to be 
the best approach for lovastatin production using 
fungal strains because it offers numerous 
advantages over liquid-state fermentation (LSF) 
such as low energy requirements, less waste 
water, and a large surface area for fungal growth 
[5-7]. In addition to treating 
hypercholesterolemia, lovastatin has other 
clinical applications for coronary heart disease, 
Alzheimer disease, renal diseases, cancer, bone 
fracture disease, and multiple sclerosis [8-10]. 
 
The present project was designed to identify the 
best lovastatin-producing fungal strain and 
optimize fermentation parameters using agro 
industrial wastes as carrier substrates. This 
information is valuable for enhancing the bulk 
production of the cholesterol-lowering drug 
lovastatin using indigenous sources, which 
facilitates environmental friendly management of 


















Figure 1: Structural formulae of the (A) lactone 




The pure cultures of fungal strains were isolated 
by our research group and grown on potato 
dextrose agar (PDA) slants. They were stored in 




Vogel’s medium (KH2PO4, 0.5; peptone, 0.1; 
yeast extract, 0.2; NH4NO3, 0.2; (NH4)2SO4, 0.4; 
MgSO4, 0.02; glucose, 50 %; trisodium citrate, 
0.5 g/100mL) was prepared in 500-mL flasks. 
The medium pH was maintained at 5.5 using 
0.1M NaOH/HCl solutions. It was sterilized in an 
autoclave at 121 °C for 15 min. Fungi spores 
were picked by loop and added into the flask. 
These flasks were positioned in an orbital shaker 




Spores were counted using a hemocytometer 
under low-power microscope using the method of 
Kolmer et al [11].  
 
Fermentation medium cultivation 
 
A comparison of two fermentation techniques 
was made using 250-mL conical flasks kept in a 
temperature-controlled incubator. For SSF, 5 g 
wheat bran was placed in triplicate flasks, and 
inoculum medium was added to keep the 
substrate at 60 % moisture. After maintaining the 
pH at 5.5, the flasks were sterilized in an 
autoclave for 15 min at 121 °C. Next, 5 mL 
spores of individual fungal strains were 
inoculated in separate flasks and placed in an 
incubator for 72 h. For LSF, 100 mL Vogel 
medium was placed in 250-mL conical flasks. 
The samples weresterilized at 121 °C for 15 min 
in an autoclave after verifying the pH. After 
cooling to room temperature, they were 
inoculated with 5 mL of fungal spores individually 




For SSF, distilled water was added to bring the 
volume up to 100 mL, and the flasks were placed 
on a shaker for 1h. These flasks were then 
acidified with 10 % 1 N HCl to pH 3.0 after 72 h 
for both SSF and LSF. An equal volume of ethyl 
acetate was added to the acidified broth, which 
was kept on a shaker for 2 h at 70 °C. This broth 
was filtered to separate out the biomass and 
filtrate, followed by centrifugation at 4,000 g for 8 
min before the upper phase was collected. Next, 
10 mL 1 % trifluoroacetic acid was added to 1 mL 
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of the organic phase for the lactonization 




Lovastatin samples were analyzed using high-
performance liquid chromatography (HPLC). The 
concentrated lovastatin was diluted at a 1:1 ratio 
with acetonitrile and passed through a filtration 
assembly (0.45 μm) The samples (20 µL) were 
injected into the HPLC apparatus (Shimadzu LC-
10AT) by syringe and analyzed with a UV 
detector at 238 nm and Shim pack CLS-ODS (C-
18) column at a flow rate of 1mL/min. The mobile 
phase consisted of 0.1 % phosphoric acid and 
acetonitrile with a volume ratio of 40:60 [12]. 
 
Kinetic growth parameter determination 
 
All kinetic parameters for lovastatin yield and 
biomass were calculated by the method as 
described by Okpokwasili and Nweke [13]. The 
kinetic parameters were studied before and after 





Comparisons of means were done by Duncan’s 
multiple range (DMR) tests, and the statistical 
significance of differences among means was 
estimated by analysis of variance (ANOVA) 




This study was performed to screen three 
Aspergilli strains (Aspergillus flavipes GCBL-72, 
Aspergillus flavus GCBL-60, and Aspergillus 
niger GCBL-45) and compare two fermentation 
techniques for natural lovastatin production using 
wheat bran, wheat straw, corn stover, and 
banana stalk as carrier substrates. It was found 
that the Aspergillus flavus GCBL-60 strain had 
the best capacity to produce lovastatin (23.57± 
1.31 mg/100mL) using wheat bran and the SSF 
technique (Figure 2) as compared with the LSF 
technique (16.42 ± 2.61 mg/100mL). 
 
Fermentation parameter optimization 
 
An optimum pH is necessary for all biological 
processes because living things are sensitive to 
pH change. The greatest amount of lovastatin 
was produced (23.33 ± 1.57 mg/100mL) with a 
dry cell mass (5.83 ± 0.051g) at pH 5.5 by 
Aspergillus flavus GCBL-60 (Figure 3A) using 
SSF. Initially, lovastatin production was 
enhanced by increasing the pH (3.0-5.5), and it 
was gradually decreased by further increasing 
the pH. 
 
Temperature is one of the most useful 
fermentation factors to optimize because it has a 
direct influence on lovastatin production. The 
maximum yield of lovastatin obtained was 25.30 
± 1.75 mg/100mL with a dry cell mass of 6.36 ± 
0.93 g by Aspergillus flavus GCBL-60 at 35 °C 
(Figure 3B). 
 
To attain maximize lovastatin yield, media were 
prepared in different conical flasks with various 
inoculum sizes (1.0-5.0 mL). The maximum 
lovastatin yield (26.68 ± 1.34 mg/100mL) and dry 
cell mass (6.34 ± 1.21 g) were found at 3.0 
(Figure 3C). Moisture content optimization is 
necessary for maximum production of secondary 
metabolites in SSF. A lower moisture level is 
very important to avoid fermentation medium 
contamination and suboptimal product formation 
due to reduced mass transfer processes, such as 
diffusion of gas and solutes to the cell. It was 
observed that the maximum lovastatin yield 
(27.88 mg/100 mL) was obtained at 60 % 
moisture content using wheat bran by Aspergillus 
flavus GCBL-60 (Figure 3D). 
 
           
 
Figure 2: Screening of three fungal strains (Aspergillus niger GCBL-45, Aspergillus flavipes GCBL-
72, and Aspergillus flavus GCBL-60) for lovastatin production in (A) LSF and (B) SSF. Values (mean± 
SD, n= 3, p≤0.05) 
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Figure 3: Effects of (A) pH, (B) temperature, (C) inoculum size, (D) moisture content and incubation time on 
lovastatin production by Aspergillus flavus GCBL-60 using wheat bran in SSF. Values (mean± SD, n= 3, p≤0.05) 
 
Time is one of the most important factors for 
optimizing any fermentation medium. It was 
found that the optimum incubation time was 96 h 
with maximum lovastatin production (28.41 ± 
0.33 mg/100 mL) for Aspergillus flavus GCBL-60 
(Figure 3E). A longer incubation time did not 
enhance lovastatin production. This might be due 
to fungal strain age, nutrient depletion, and low 
nitrogen availability in the medium. 
 
Kinetic parameters  
 
Kinetic parameters of substrate consumption and 
product formation were estimated before and 
after optimization of lovastatin production by 
Aspergillus flavus GCBL-60 (Table 1). After 
optimization, the highest lovastatin quantity 
(28.41 ± 0.33 mg/100 mL) was noted for 
Aspergillus flavus GCBL-60. Growth parameters 
were also compared before and after 
optimization (Table 1). Before optimization, 
Aspergillus flavus GCBL-60 exhibited levels of 
substrate consumption parameters Yx/s and Yp/x 
and product formation parameter Yp/s (1.43, 
3.18 and 0.44 mg/g, respectively). On 
optimization, it was observed that these growth 
parameters were further enhanced to 2.74, 5.60 
and 0.489 mg/g, respectively (Table 1). It was 
also observed that the Qs, qs, and Yx/s 
parameters significantly increased after 
optimization, indicating that Aspergillus flavus 
Javed et al 
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Aµ(h-1) 0.084 0.190 
BYx/s 1.43 2.74 
CYp/x,  3.18 5.60 
Dqs(g/g/h) 0.023 0.021 
EQs(g/L/h) 0.16 0.11 
Product formation  FQx(g/L/h) 0.072 0.056 
GYp/s 0.44 0.489 
Hqp (Product/h/g)  0.033 0.058 
IQp (Product/L/h)            0.23              0.314 
Lovastatin was produced in Vogel’s medium with an initial sugar concentration of 20 g/L (w/v). Aµ (h-1), Specific 
growth rate; BYx/s, Drug produced/g glucose consumed; CYp/x, Drug produced/g cell formed; Dqs (g/g/h), g sugar 
consumed/g cells/h; EQs (g/L/h), g sugar consumed/L/h; FQx (g/L/h), g cells formed/L/h; GYp/s, Cell formed/g 
sugar consumed; Hqp (Product/g/h), Drug produced/g cells/h; IQp (Product/L/h), drug produced/L/h 
 
GCBL-60 grew faster under the new conditions. 
The maximum product formed (QP) was 0.23 
g/L/h before optimization, and this improved to 




Fermentation is a technique that produces 
secondary metabolites using inexpensive raw 
materials under SSF. It offers major advantages 
including cost-effective raw material, simple 
downstream processing, and less water use [15]. 
In SSF, fungus directly adsorbs on the substrate 
and uses it as an energy source to secrete a 
higher amount of the desired product. Substrate 
particle size is very important to provide higher 
porosity for better heat and mass transfer for 
maximum lovastatin production. Highest 
lovastatin production (85.88 mg/L) by Aspergillus 
flavus UICC 360 was reported by 
Mangunwardoyo et al [16], and a maximum 
lovastatin concentration (113 μg/mL) by P. 
ostreatus was observed by Lakshmanan and 
Radha [17].  
 
Biological fluids are very sensitive to changes in 
physiological pH. However, maximum lovastatin 
production was observed at pH 7.0 by Latha et al 
[22]. We found that further increase in pH 
decreases product formation, while low pH 
prevents contamination and also denatures or 
inactivates the fungal strain. The pH range for 
most of the fungi is reported as 3.5-7.0. The pH 
affects the transport of different ions and 
substances across the cell membrane, which 
supports product formation and cell growth [1]. 
 
Fermentation medium temperature is one of the 
most important factors that directly influences 
microorganism growth. Temperature affects the 
production of secondary metabolites, and this 
effect is variable according to media composition. 
It was previously reported that the maximum 
lovastatin production occurs at 28 °C, and further 
increases in temperature decrease the yield [19]. 
Optimum lovastatin production was observed at 
30 °C. This temperature might be best for the 
sporulation, proliferation, and growth of mycelial 
masses. However, Attalla et al [20] obtained 
maximum lovastatin production at 28 - 30 °C.  
 
Appropriate inoculum size is necessary in SSF 
processes because inappropriate sizes may lead 
to inaccurate data. Inoculum with too few spores 
may lead to insufficient biomass, while too many 
spores results in biomass overproduction and 
subsequent depletion of nutrients in the medium. 
These findings are in agreement with those of 
Latha et al [22], who reported the highest amount 
of lovastatin produced with a 2 % culture of 
Aspergillus fischeri. Some other studies reported 
varying inoculum size; Hajjaj et al [21] and 
Samiee et al [23] found that 3 and 10 % inoculum 
sizes, respectively, were best for maximum 
lovastatin production by Aspergillus terreus. 
 
Moisture content is one of the most critical 
factors affecting SSF. An optimum moisture level 
minimizes the risk of fermentation medium 
contamination. Low moisture may support the 
availability of sufficient oxygen, but it also 
reduces metabolic activity, which may decrease 
lovastatin production. Conversely, higher 
moisture level decreases oxygen availability due 
to insufficient air present in the void volume and 
poor lovastatin production. It was evident from 
our study that the 2 % inoculum size yielded the 
most lovastatin, and further increasing moisture 
content lowered production. Latha et al [22] 
reported the highest lovastatin yield at 60 % 
moisture content. 
 
Incubation time is another important factor to 
optimize for maximum lovastatin production with 
SSF. It is generally considered that a short 
fermentation period can effectively contribute to 
increasing profitability on an industrial scale. 
Lovastatin is a secondary metabolite produced 
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during the stationary phase of growth [24]. Latha 
et al [22] reported a maximum yield of lovastatin 
at 7.43 mg/g of dry substrate with 168 h of 
fermentation time. Maximum lovastatin 
production after 96 h may be due to the fact that 
it was produced as a result of the secondary 
microorganism growth. The subsequent 
decrease in lovastatin production was due to 
feedback inhibition by the existing lovastatin. 
Mukhtar et al [24] found maximum lovastatin 
production (1,699.87 ± 0.08 µg/mL) by 
Aspergillus terreus after 120 h incubation.  
 
Overall, kinetic parameters exhibited maximum 
product formation on substrate utilization during 
the fermentation process. Haq et al [25] reported 
that the cell growth rate of A. niger GCB-16 was 
0.193/h by GCB-16 for citric acid production. 
Moreover, Ali et al [26] found that the cell growth 
rate of Aspergillus niger was 0.122/h. However, 
our selected strain Aspergillus flavus GCBL-60 
showed the maximum cell growth rate following 




The findings of current study indicate that the 
combination of Aspergillus flavus with wheat bran 
and solid state fermentation technique is best for 
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